Scarica l'app Stockscreener
3.06
2.86%
-0.09
Dopo l'orario di chiusura:
3.06
Absci Corp Borsa (ABSI) Ultime notizie
Highs Report: Can Absci Corporation lead its sector in growth2026 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Update Recap: Is Absci Corporation a top pick in the sectorWeekly Trade Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Is now the right time to enter Absci CorporationQuarterly Growth Report & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Targets Report: Will Absci Corporation benefit from government policy2026 Weekly Recap & Weekly High Potential Stock Alerts - baoquankhu1.vn
Insider Trends: Will Absci Corporation benefit from government policy2026 Breakouts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Absci Corp. Earnings Call: Betting on ABS-201 - TipRanks
Redmile Group (ABSI) reports 5.4% Absci stake as share count rises - Stock Titan
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Vanguard affiliates to report separately as ABSI holdings shift (ABSI) - Stock Titan
Here's Why We're Watching Absci's (NASDAQ:ABSI) Cash Burn Situation - finance.yahoo.com
What is HC Wainwright's Forecast for Absci FY2030 Earnings? - marketbeat.com
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $4.2 to $8 - 富途牛牛
Absci Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Needham Reiterates Buy Rating on ABSI with Price Target of $7.00 - GuruFocus
Absci Shares Fall on Wider 4Q Loss, Lower Revenue - news.futunn.com
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
Absci reports Q4 EPS (20c), consensus (17c) - TipRanks
Absci’s AI-Native Integrated Drug Creation Platform: Advancing Antibody Therapeutics and Biopharma Innovation - Minichart
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions - Bitget
Absci Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips - Investing.com
Absci Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data - Stock Titan
Absci earnings missed by $0.02, revenue fell short of estimates - Investing.com
Absci (NASDAQ:ABSI) Announces Quarterly Earnings Results - MarketBeat
Absci shares slip nearly 4% on Q4 revenue miss, wider loss than expected - Investing.com
Absci 10-K: Partner revenue $2.8M, Net loss $115.2M, EPS $(0.84) - TradingView
ABSCI ($ABSI) Releases Q4 2025 Earnings - Quiver Quantitative
Absci (NASDAQ: ABSI) highlights ABS-201 trial progress and AI drug platform - Stock Titan
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results - globenewswire.com
AbSci Corp options imply 13.4% move in share price post-earnings - TipRanks
Absci forms advisory board for endometriosis drug program - investing.com
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic - The Manila Times
Absci forms advisory board for endometriosis drug program By Investing.com - Investing.com Canada
Absci taps Yale, Mayo experts for non-hormonal endometriosis drug - Stock Titan
Earnings Scheduled For March 24, 2026 - Benzinga
Earnings To Watch: Absci Corp (ABSI) Reports Q4 2025 Result - GuruFocus
ABSI Technical Analysis | Trend, Signals & Chart Patterns | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Form 8K Absci Corp For: 14 January - Investing.com
Absci Corp expected to post a loss of 19 cents a shareEarnings Preview - TradingView
ABSI PE Ratio & Valuation, Is ABSI Overvalued - Intellectia AI
ABSI Absci Corporation NASDAQ $2.86 on 19 Mar 2026: earnings Mar 24 could shift targets - Meyka
Earnings Preview: Absci Corp to Report Financial Results Post-market on March 24 - 富途牛牛
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):